FLT4

From Wikipedia, the free encyclopedia

Fms-related tyrosine kinase 4

Identifiers

FLT4; FLT41; PCL; VEGFR3

External IDs

OMIM: 136352 MGI: 95561 HomoloGene: 7321

Gene ontology
Molecular Function:	• nucleotide binding • protein-tyrosine kinase activity • receptor activity • vascular endothelial growth factor receptor activity • protein binding • ATP binding • transferase activity
Cellular Component:	• integral to plasma membrane • membrane
Biological Process:	• protein amino acid phosphorylation • transmembrane receptor protein tyrosine kinase signaling pathway

Orthologs

Human

Mouse

Refseq

NM_002020 (mRNA)
NP_002011 (protein)

NM_008029 (mRNA)
NP_032055 (protein)

Location

Chr 5: 179.96 - 180.01 Mb

Chr 11: 49.45 - 49.5 Mb

Pubmed search

[1]

[2]

Fms-related tyrosine kinase 4, also known as FLT4, is a human gene.^[1]

[edit] See also

VEGF receptors

[edit] References

^ Entrez Gene: FLT4 fms-related tyrosine kinase 4.

[edit] Further reading

Petrova TV, Makinen T, Alitalo K (1999). "Signaling via vascular endothelial growth factor receptors.". Exp. Cell Res. 253 (1): 117–30. doi:10.1006/excr.1999.4707. PMID 10579917.
Aprelikova O, Pajusola K, Partanen J, et al. (1992). "FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter.". Cancer Res. 52 (3): 746–8. PMID 1310071.
Galland F, Karamysheva A, Mattei MG, et al. (1992). "Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene.". Genomics 13 (2): 475–8. PMID 1319394.
Pajusola K, Aprelikova O, Korhonen J, et al. (1992). "FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.". Cancer Res. 52 (20): 5738–43. PMID 1327515.
Fournier E, Dubreuil P, Birnbaum D, Borg JP (1995). "Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.". Oncogene 11 (5): 921–31. PMID 7675451.
Pajusola K, Aprelikova O, Armstrong E, et al. (1993). "Two human FLT4 receptor tyrosine kinase isoforms with distinct carboxy terminal tails are produced by alternative processing of primary transcripts.". Oncogene 8 (11): 2931–7. PMID 7692369.
Pajusola K, Aprelikova O, Pelicci G, et al. (1994). "Signalling properties of FLT4, a proteolytically processed receptor tyrosine kinase related to two VEGF receptors.". Oncogene 9 (12): 3545–55. PMID 7970715.
Galland F, Karamysheva A, Pebusque MJ, et al. (1993). "The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor.". Oncogene 8 (5): 1233–40. PMID 8386825.
Fournier E, Rosnet O, Marchetto S, et al. (1996). "Interaction with the phosphotyrosine binding domain/phosphotyrosine interacting domain of SHC is required for the transforming activity of the FLT4/VEGFR3 receptor tyrosine kinase.". J. Biol. Chem. 271 (22): 12956–63. PMID 8662748.
Lee J, Gray A, Yuan J, et al. (1996). "Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4.". Proc. Natl. Acad. Sci. U.S.A. 93 (5): 1988–92. PMID 8700872.
Kukk E, Lymboussaki A, Taira S, et al. (1997). "VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development.". Development 122 (12): 3829–37. PMID 9012504.
Achen MG, Jeltsch M, Kukk E, et al. (1998). "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).". Proc. Natl. Acad. Sci. U.S.A. 95 (2): 548–53. PMID 9435229.
Ferrell RE, Levinson KL, Esman JH, et al. (1999). "Hereditary lymphedema: evidence for linkage and genetic heterogeneity.". Hum. Mol. Genet. 7 (13): 2073–8. PMID 9817924.
Fournier E, Blaikie P, Rosnet O, et al. (1999). "Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling.". Oncogene 18 (2): 507–14. doi:10.1038/sj.onc.1202315. PMID 9927207.
Karkkainen MJ, Ferrell RE, Lawrence EC, et al. (2000). "Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.". Nat. Genet. 25 (2): 153–9. doi:10.1038/75997. PMID 10835628.
Irrthum A, Karkkainen MJ, Devriendt K, et al. (2000). "Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase.". Am. J. Hum. Genet. 67 (2): 295–301. PMID 10856194.
Wang JF, Zhang XF, Groopman JE (2001). "Stimulation of beta 1 integrin induces tyrosine phosphorylation of vascular endothelial growth factor receptor-3 and modulates cell migration.". J. Biol. Chem. 276 (45): 41950–7. doi:10.1074/jbc.M101370200. PMID 11553610.
Baldwin ME, Roufail S, Halford MM, et al. (2001). "Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis.". J. Biol. Chem. 276 (47): 44307–14. doi:10.1074/jbc.M106188200. PMID 11574540.
Walter JW, North PE, Waner M, et al. (2002). "Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma.". Genes Chromosomes Cancer 33 (3): 295–303. PMID 11807987.